These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33953347)

  • 1. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
    Salvianti F; Gelmini S; Mancini I; Pazzagli M; Pillozzi S; Giommoni E; Brugia M; Di Costanzo F; Galardi F; De Luca F; Castiglione F; Messerini L; Pinzani P; Antonuzzo L
    Br J Cancer; 2021 Jul; 125(1):94-100. PubMed ID: 33953347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.
    Bádon ES; Mokánszki A; Mónus A; András C; Méhes G
    Mol Cell Probes; 2023 Feb; 67():101891. PubMed ID: 36586518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.
    Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC
    Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer.
    Kondo Y; Hayashi K; Kawakami K; Miwa Y; Hayashi H; Yamamoto M
    BMC Cancer; 2017 May; 17(1):311. PubMed ID: 28468669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities.
    Liebs S; Eder T; Klauschen F; Schütte M; Yaspo ML; Keilholz U; Tinhofer I; Kidess-Sigal E; Braunholz D
    Oncogene; 2021 Aug; 40(33):5204-5212. PubMed ID: 34230613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
    PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.
    Buim ME; Fanelli MF; Souza VS; Romero J; Abdallah EA; Mello CA; Alves V; Ocea LM; Mingues NB; Barbosa PN; Tyng CJ; Chojniak R; Chinen LT
    Cancer Biol Ther; 2015; 16(9):1289-95. PubMed ID: 26252055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer.
    Raimondi C; Nicolazzo C; Gradilone A; Giannini G; De Falco E; Chimenti I; Varriale E; Hauch S; Plappert L; Cortesi E; Gazzaniga P
    Cancer Biol Ther; 2014 May; 15(5):496-503. PubMed ID: 24521660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
    Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
    PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.
    Barault L; Amatu A; Siravegna G; Ponzetti A; Moran S; Cassingena A; Mussolin B; Falcomatà C; Binder AM; Cristiano C; Oddo D; Guarrera S; Cancelliere C; Bustreo S; Bencardino K; Maden S; Vanzati A; Zavattari P; Matullo G; Truini M; Grady WM; Racca P; Michels KB; Siena S; Esteller M; Bardelli A; Sartore-Bianchi A; Di Nicolantonio F
    Gut; 2018 Nov; 67(11):1995-2005. PubMed ID: 28982739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays.
    Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M
    Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
    Xie W; Xie L; Song X
    Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.